Immunotherapy is increasingly being used to treat cancer because of its significant benefits to patients. This treatment is characterized by high efficiency and longevity by maintaining the response of the immune system over time. Many promising studies are currently being conducted. However, immunotherapy has one major limitation. It remains largely ineffective in the treatment of pediatric cancer. In fact, this therapeutic approach is based on a basic concept: tumor-specific genetic mutations can be identified as non-self by the immune system. However, in childhood cancer, these mutations are rare.
A study conducted by the team of Dr. Olivier Delatra, Chief Insom Research Director of the Cancer, Diversity, Instability and Plasticity Unit (CHIP – Institut Curie / Inserm / University of Paris), Just highlighted The expression of highly specific genes in Ewing’s sarcoma, And more specifically in specific pediatric sarcomas and tumors.
These results were published in the journal May 11, 2022 Molecular cellsIn support of the National Cancer League, L’Etoile de Martin, the Race for Hope, M la vie avec Lisa, ADAM, Couleur Jade, Dans les pas du Géant, Courir pour Mathieu, Marabout de Ficelle, Olivier Chape, Les Bagouzamanon, Children and Health , Claire’s friend, pour un alan lucas.
The genetic mutations of sarcomas exhibit fancy activity
Many cancers are characterized by a special genetic mutation called “gene fusion” that results in the release of oncogenic proteins (transcription factors). About 95% of Ewing tumors are due to a characteristic genetic fusion: in most cases it is a transplant Which occurs between chromosomes 11 and 22 and results in an abnormal protein synthesis, transcription factor EWS-FLI-1. Fusions between the two genes are found in a large number of sarcomas, resulting in the presence of these special transcription factors called “chimeric” Oncogenes “.
In the wake of this first discovery, the Institute is taking another step towards understanding the important role of EWS-FLI-1 in childhood tumor diversity and plasticity team led by Dr. Delatt. Researchers have shown that this Ewing sarcoma-specific transcription factor induces the expression of a set of genes in a region of the genome that is usually “silent”, in other words, not replicated. Their results indicate that these “neogenes” could be translated into highly specific peptides because they are strongly expressed in Ewing’s sarcoma cells, where they are absent from the body’s normal cells. The role of these transcription factors in metastatic processes is already known, but this is the first time such activity has been observed.
The presence of this particular genetic mutation is found in many pediatric cancers, thus increasing the likelihood of immunotherapy targeting these tumor-specific proteins. This discovery could prove revolutionary for the management of childhood tumors, the second leading cause of death in children under 15 today.
Describe it Dr. Olivia Delatre, Chief Insom Research Director for Cancer, Variation, Instability and Plasticity – Chip (Curie Institute / INSERM / University of Paris).
“We now need to show that these newly identified proteins can form the real therapeutic goal for the development of immunotherapy. This is the subject of research we are currently conducting jointly with the Immunity and Cancer Unit Curie / Insarum / University of Paris.” Clinical Immunology Laboratory run by Dr. Olivier Lantz ” Dr. Delatre finished.
More generally, study authors have shown that these hundreds of neogenes can be detected in a variety of cancers identified by oncogenic chimeric transcription factors. The high specificity and recurrence of these peptides in different types of childhood sarcoma make them a promising therapeutic target for the development of immunotherapy in the treatment of cancer in their children.
Read the post
Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions. Julien Vibert, Olivier Soulnier, Celine Colin, Florian Petit, Kyra Jay Borgman, Jerome Vigniew, Maud Gautier, Sakina Zaidi, Gayle Pierron, Sarah Watson, Nadez Gruel, Clemens-Wennell, Sophie , Karine Laud-Duval, Véronique Hill, Sandrine Grossetête, Florent Dingli, Damarys Loew, Jacob Torrejon, Olivier Ayrault, Martin F. Orth, Thomas GP Grünewald, Didier Surdez, Antoine Coulon, Joshua J. Waterfall, Olivier Delattre.
Molecular Cells (2022), https://doi.org/10.1016/j.molcel.2022.04.019
 The second most common malignant bone tumor after osteosarcoma in adolescents and young adults, Ewing’s sarcoma develops mainly in the bones of the pelvis, ribs, femur, fibula, and tibias. Through its strong invasiveness, Ewing’s sarcoma can cause other cancerous foci to appear in the body, especially in the lungs, skeleton, and bone marrow.
 Chromosomal rearrangement that involves the reciprocal exchange of chromosomal components between non-homologous chromosomes.
 When a single DNA sequence comes from multiple transcripts or parent sequences.
Treatment of pediatric cancer at the Institute Curie
Every year in France, about 2,200 new cases of pediatric cancer are diagnosed. If more than 80% of children survive after five years of diagnosis, it is important to develop new therapeutic strategies for those who have not yet been cured and to reduce the sequence of conventional treatments. At Institute Curie, 300 to 400 young patients are cared for each year by a multidisciplinary team at the SIREDO Center (Care, Innovation, Research in Oncology for Children, Adolescents and Young Adults) run by Dr. Delatre. With the help of associations, they conduct basic, translational, and clinical research with a strong specialization in solid tumors: neuroblastoma, medulloblastoma, Ewing’s sarcoma, retinoblastoma, and specific brain tumors.